ViroLogic Launches VLink Online System for HIV Resistance Test Reporting

ViroLogic Launches VLink Online System for HIV Resistance Test Reporting
Internet Access to Test Results Adds Convenience and Reduces Turnaround Time 


SOUTH SAN FRANCISCO, Calif., March 30  /PRNewswire-FirstCall/ -- ViroLogic, Inc.
 today announced the launch of VLink online test reporting for its comprehensive
portfolio of HIV drug resistance assays, PhenoSense GT(TM), PhenoSense(TM) HIV
and GeneSeq(TM) HIV.  The VLink system is designed to offer a fast and
convenient way for healthcare professionals to access test results via a secure
Internet connection.

"Creating secure and convenient online access to up-to-date test results will
help improve patient care," said Stephen Becker, MD, Associate Clinical
Professor of Medicine at the University ofCalifornia, San Francisco and an HIV
specialist in private practice.  "ViroLogic's online reporting system is a
useful tool that places current and historical testing information at my
fingertips and provides efficiencies that are not realized by paper-based
systems."

Increasingly, healthcare organizations are improving efficiency through the
adoption of electronic or web-based procedures.  ViroLogic's secure new online
system facilitates data analysis, allowing examination of historical patient
resistance data to help identify resistance patterns in patients over time. 
Importantly, this service is expected to shorten the time period between sample
submission and reporting of results.  The Company believes the system is fully
compliant with the patient confidentiality regulations outlined in the Health
Insurance Portability and Accountability Act (HIPAA).

"VLink is intended to facilitate rapid HIPAA-compliant access to test results,
enabling more prompt and informed management of patients withHIV," said Tien
Bui, ViroLogic's Vice President of Sales and Marketing.  "We are committed to
building on our leadership position in HIV resistance testing through continued
enhancement of our products and services to healthcare providers."

Interestedcustomers may register for this service by contacting ViroLogic's
Customer Service department at 800-777-0177 or by e-mail at .  The online
reporting service is also available to ViroLogic's pharmaceutical and clinical
research collaborators.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis.  The Company's
products aredesigned to help doctors optimize treatment regimens for their
patients that lead to better outcomes and reduced costs.  The Company's
technology is also being used by numerous biopharmaceutical companies to develop
new and improved antiviral therapeutics and vaccines targeted at emerging
drug-resistant viruses.  More information about the Company and its technology
can be found on its web site at http://www.virologic.com/.

Certain statements in this press release are forward-looking, including
statements relating to overall turnaround time, efficiencies resulting from
electronic reporting, and compliance with HIPAA.  These forward-looking
statements are subject to risks and uncertainties and other factors, which may
cause actual results to differmaterially from the anticipated results or other
expectations expressed in such forward-looking statements.  These risks and
uncertainties include, but are not limited to, the risks that the Company's
products may not perform in the same manner as indicated in this press release,
whether ViroLogic successfully introduces new products, whether others introduce
competitive products, the risk that the Company's products for patient testing
may not continue to be accepted or that increased demand from drug development
partners may not develop as anticipated, the risk that gross margins may not
increase as expected, the risk that ViroLogic may not continue to realize
anticipated benefits from its cost-cutting measures, the timing of
pharmaceutical company clinical trials, whether payors will authorize
reimbursement for its products, whether the FDA or any other agency will decide
to regulate ViroLogic's products or services, whether the Company will encounter
problems or delays in automating its processes, whether ViroLogic successfully
introduces new products, whether others introduce competitive products, whether
intellectual property underlying the Company's PhenoSense technology is
adequate, whether licenses to third party technology will be available, whether
ViroLogic is able to build brand loyalty and expand revenues, and whether
ViroLogic will be able to raise sufficient capital when required.  For a
discussion of other factors that may cause ViroLogic's actual events to differ
from those projected, please refer to the Company's most recent annual report on
Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent
filings with the Securities and Exchange Commission. 

DATASOURCE: ViroLogic, Inc.



CONTACT:  Karen Wilson,CFO of ViroLogic, [phone], or





Web site:  http://www.virologic.com/ 

Copyright